Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
- Gebhart, G.
- Keyaerts, M.
- Guiot, T.
- Flamen, P.
- Ruiz-Borrego, M.
- Stradella, A.
- Bermejo, B.
- Escriva-de-Romani, S.
- Calvo Martínez, L.
- Ribelles, N.
- Fernandez-Abad, M.
- Albacar, C.
- Colleoni, M.
- Garrigos, L.
- Atienza de Frutos, M.
- Dalenc, F.
- Prat, A.
- Marmé, F.
- Schmid, P.
- Kerrou, K.
- Braga, S.
- Gener, P.
- Sampayo-Cordero, M.
- Cortés, J.
- Pérez-García, J.M.
- Llombart-Cussac, A.
- Montrer des auteurs +
ISSN: 1535-5667
Année de publication: 2024
Volumen: 65
Número: 5
Pages: 708-713
Type: Article